西格列汀改善2型糖尿病患者胰岛B细胞功能的Meta分析

发布时间：2018-07-11 18:25

本文选题：西格列汀 + 胰岛B细胞功能　；参考：《中国药房》2017年15期

【摘要】：目的:系统评价西格列汀改善2型糖尿病患者胰岛B细胞功能的效果,为临床提供循证参考。方法:计算机检索Pub Med、Cochrane图书馆、EMBase、相关期刊论文、万方数据库、中文科技期刊数据库和中国生物医学文献数据库,收集西格列汀单药或联合常规方案(试验组)对比安慰剂单用或联合常规方案(对照组)治疗2型糖尿病的随机对照试验(RCT),由两位研究者根据纳入与排除标准独立筛选文献、提取资料,按照Cochrane系统评价员手册5.1.0评价纳入研究的方法学质量后,采用Rev Man 5.3统计软件进行Meta分析。结果:纳入了5项RCT,合计1 253例患者。Meta分析结果显示,试验组患者胰岛B细胞功能指数(Homa-B)变化值[西格列汀单药治疗组:MD=9.21,95%CI(4.16,14.25),P0.001;联合用药组:MD=7.24,95%CI(0.80,13.68),P=0.03]和胰岛素抵抗指数(Homa-IR)变化值[西格列汀单药治疗组:MD=-0.40,95%CI(-0.44,-0.36),P0.001;联合用药组:MD=-0.35,95%CI(-0.63,-0.07),P=0.02]均显著优于对照组,差异均有统计学意义。结论:西格列汀在改善胰岛B细胞功能及胰岛素抵抗方面有一定效果。
[Abstract]:Objective: to evaluate the effect of siglitatin on improving islet B cell function in patients with type 2 diabetes mellitus. Methods: a computer-based search was conducted for Pub Medbin Cochrane Library EMBase, full text Database of Chinese Journals, Wanfang Database, Chinese Sci-tech Journals Database and Chinese Biomedical Literature Database. A randomized controlled trial (RCT) of ciglutin alone or in combination with routine regimen (trial group) versus placebo alone or conventional regimen (control group) in the treatment of type 2 diabetes was collected, and the two researchers independently screened the literature according to the inclusion and exclusion criteria. After extracting the data and evaluating the methodological quality of the study according to the Cochrane systematic evaluator's manual 5.1.0, the Meta-analysis was carried out with Rev Man 5.3 statistical software. Results: a total of 1 253 patients were included in 5 RCTs. Meta-analysis showed that, The changes of islet B cell function index (Homa-B) and insulin resistance index (Homa-B) in the trial group were significantly better than those in the control group (P 0.001). The changes of islet B cell function index (Homa-B) and insulin resistance index (Homa-IR) in the trial group were significantly better than those in the control group. The difference was statistically significant. Conclusion: siglitatin can improve the function of islet B cells and insulin resistance.
【作者单位】：北京医院国家老年医学中心药学部;
【基金】：“重大新药创制”科技重大专项(No.2012ZX09303-008-002)
【分类号】：R587.1

【相似文献】